Browse > Article

A Case of Pseudodeficiency in a Potential Late Onset Pompe Disease Carrier, with Double Dual Variant, Each in cis Formation  

Seung Ho, Kim (Department of Pediatrics, Dankook University Hospital)
Goo Lyeon, Kim (Department of Pediatrics, Dankook University Hospital)
Young Pyo, Chang (Department of Pediatrics, Dankook University Hospital)
Dong Hwan, Lee (Department of Pediatrics, Dankook University Hospital)
Publication Information
Journal of The Korean Society of Inherited Metabolic disease / v.22, no.2, 2022 , pp. 58-62 More about this Journal
Abstract
Pompe disease (PD) is an autosomal recessive genetic disorder caused by a deficiency of the lysosomal enzyme acid α-glucosidase (GAA). It is easy to hastily diagnose as patients if they have two pathogenic variants. Clinical pathologists misdiagnosed our infant and her mother as PD. Here, we report a case of pseudodeficiency in a potential late-onset Pompe disease (LOPD) carrier with a double dual variant, each in cis formation in a 3-month infant. The person who has two pathogenic variants was diagnosed as a carrier, not a patient. It was first reported in Korea. The patient had: two likely pathogenic heterozygous mutations on exon #4: c.752C>T (p.Ser251Leu), c.761C>T (p.Ser254Leu), and a heterozygous mutation on exon #12: c.1726G>A (p.Gly576Ser), also with a heterozygous mutation on exon #15: c.2065G>A (p.Glu689Lys). By presenting this case we emphasize the possibility of cis formation of genes which may cause pseudodeficiency, and potential LOPD carrier form. Hereby we suggest that thorough evaluation of GAA gene is essential among whom initially diagnosed as PD.
Keywords
Pompe disease; Dual variant in cis formation; Pseudodeficiency; Potential late onset Pompe disease carrier;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-88.    DOI
2 Labrousse P, Chien YH, Pomponio RJ, Keutzer J, Lee NC, Akmaev VR, et al. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab 2010;99:379-83.    DOI
3 Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 2008;29:E13-26.    DOI
4 Kim MS, Song A, Im M, Huh J, Kang IS, Song J, et al. Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center. Korean J Pediatr 2019;62:224-34.    DOI
5 Sawada T, Kido J, Nakamura K. Newborn screening for pompe disease. Int J Neonatal Screen 2020;6:31. 
6 Sawada T, Kido J, Sugawara K, Momosaki K, Yoshida S, Kojima-Ishii K, et al. Current status of newborn screening for Pompe disease in Japan. Orphanet J Rare Dis 2021;16:516. 
7 Chien YH, Hwu WL, Lee NC. Newborn screening: Taiwanese experience. Ann Transl Med 2019;7:281. 
8 Klug TL, Swarts LB, Washburn J, Brannen C, Kiesling JL. Lessons learned from pompe disease newborn screening and follow-up. Int J Neonatal Screen 2020;6:11. 
9 Park KS. Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. Mol Genet Metab Rep 2021;27:100734. 
10 Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 2011;158:1023-7.   DOI